artenimol has been researched along with Bile Duct Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H; Li, K; Liu, X; Tan, C; Wang, Z; Zhang, H | 1 |
| Ferraresi, A; Isidoro, C; Loilome, W; Namwat, N; Thongchot, S; Vidoni, C; Yongvanit, P | 1 |
2 other study(ies) available for artenimol and Bile Duct Cancer
| Article | Year |
|---|---|
Dihydroartemisinin/miR-29b combination therapy increases the pro-apoptotic effect of dihydroartemisinin on cholangiocarcinoma cell lines by regulating Mcl-1 expression.
Topics: Apoptosis; Artemisinins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein | 2020 |
Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway.
Topics: Artemisia annua; Artemisinins; Autophagy; Beclin-1; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Death-Associated Protein Kinases; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2018 |